All News

RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
DM.sine_.jpg

Dazukibart Effective in Adults with Dermatomyositis

Jack Cush, MD

Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).

Read Article
RheumNow Podcast square

Alive in 2025 (1.10.2025)

Jack Cush, MD

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

Read Article
vaccine.jpg

Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients

Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
RheumNow Podcast square

Bah Humbug Vitamin D (12.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
eyes

Best of 2024: Diagnosing Seronegative Sjogren's Disease

Jack Cush, MD

Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy.

Read Article
mosquito.jpg

Chikungunya marches on, at a cost

Jack Cush, MD

A recent article from BMC Global Health suggests that between 2011 and 2020, the mosquito-borne disease chikungunya, has disabled millions and likely amassed close to $50 billion in healthcare and disability-related costs in 110 countries. 

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
pregnant, pregnancy, mother, fertility

Infertility linked to post-childbrith onset of systemic autoimmune disease

EurekAlert!

Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.

Read Article
IgG4.criteria.jpg

Inebilizumab for Treatment of IgG4-Related Disease

Jack Cush, MD

Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.

Read Article
eyes

Phase 2b Study of Ianalumab in Sjögren's

Jack Cush, MD

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

Read Article
Congratulations to Jennifer Anolik, MD, PhD, being named chief of the Allergy, Immunology & Rheumatology at the Univ. of Rochester Medical Center; where she is also Assoc Chair of research & professor of Medicine, Pathology, Microbiology and Immunology, and director of the… https://t.co/jvRiZZ6u1q https://t.co/N2nFp8w6Yx
Dr. John Cush RheumNow ( View Tweet)
Dazukibart Effective in Adults with Dermatomyositis Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/Va9Z0NWHj9 https://t.co/ciM7QtEF5S

Links:

Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/rbYMCl1FcO https://t.co/LWqppg36cn

Links:

Dr. John Cush RheumNow ( View Tweet)
Serum IL-40 increased in RA (vs OA, SLE, Controls) and correlates with some clinical characteristics. IL-40 did not correlated w/ Dz activity, but was pos. assoc. w/ RA autoAbs, coagulation-related indicators, and decreased with TNFIi Rx. https://t.co/leBPKbNpf5 https://t.co/fHU8lcS4eW

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/KbHcgSIohv https://t.co/0g8X4zrq4X
Dr. John Cush RheumNow ( View Tweet)
Full Read Review of the Pulmonary Manifestations in Antisynthetase Syndrome (good reference!) https://t.co/gBLYRmHKE4 https://t.co/pUWmQCHk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/eDcx4AAnAs https://t.co/Y8Rso7h5t2
Dr. John Cush RheumNow ( View Tweet)
Autoantibodies, found in over half of adult and paediatric patients with idiopathic inflammatory myopathies (IIMs), these correlate with clinical phenotypes, aiding in classification and prognosis. https://t.co/ZRXqtEec6s https://t.co/jkUe9bRlmU

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×